TrialMalaria journal2016

Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial.

Pamela L St Jean et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.